Latest Alefacept Stories
Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Mark R. Rigby M.D., Ph.D. from Indiana University and Riley Hospital for Children in Indianapolis and sponsored by the Immune Tolerance Network (ITN) with additional support from JDRF, are published today in The Lancet Diabetes & Endocrinology.
CHICAGO, Aug. 9 /PRNewswire/ -- New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARAÂ® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight.
Findings from a cost model suggest that expenses for systemic psoriasis therapy appear to be increasing at a faster rate than inflation, and newer biologically derived treatments are more expensive than traditional systemic therapies.
Transplant patients rely on drugs to prevent graft rejection, but at the cost of serious side effects. The class of immunosuppressive drugs known as calcineurin inhibitors
First and Only Biologic Approved with Infrequent, Every Twelve-Week Maintenance Dosing BEERSE, Belgium, Jan. 22 /PRNewswire/ -- Janssen-Cilag announced today that STELARA(TM) (ustekinumab), the first in a new class of biologics, has been approved by the European Commission for use across Europe.
- A trick or prank.